Xinmaide completed a nearly 300 million yuan Series B financing.

36Kr learned that recently, "NewMed", a domestic drug delivery company, announced the completion of a nearly 300 million yuan Series B financing. This round of financing was led by Suzhou Industrial Park Yuanhe Origin Venture Capital Management Co., Ltd., with follow - on investments from existing shareholders Hongyuan Capital and Dahua Venture Capital Management Co., Ltd. Institutions such as Jinyu Maowu, Changshu Economic Development Holding Mother Fund, and Changshu Guofa Venture Capital also participated. After the completion of this financing, NewMed will focus on pulmonary drug delivery, nasal drug delivery, and other advanced drug delivery directions, continuously promote the construction of a drug delivery technology platform for innovative drugs, and further strengthen and expand its comprehensive capabilities in original R & D, precision engineering, industrialization, and global cooperation.